II. Indications
- Early Type II Diabetes Mellitus Oral Agent
- Elevated postprandial Glucose
- Consider if only used intermittently for pre-meal Hyperglycemia
III. Contraindications
- Sulfa Hypersensitivity
- Chronic Kidney Disease Stage 5 (eGFR <15 ml/min)
IV. Mechanism
- Insulin secretogogue
- Benzoic acid derived from Sulfonylureas
- Directly stimulates pancreatic beta cells (Similar to Sulfonylureas)
- Binds different sites from Sulfonylureas (Sulfonylurea Receptors 1, 1A and 1B)
- Closes ATP sensitive K+ channels
- Results in Insulin secretion
- Effects
- Predominately effects postprandial Glucose
- Faster oral absorption and onset than Sulfonylureas
- Shorter duration of binding and shorter effect than Sulfonylureas
V. Medications
- Nateglinide (Starlix): 60 mg, 120 mg
VI. Dosing
VIII. Adverse Effects
- Hypoglycemia (lower risk than Sulfonylureas)
IX. Safety
- Pregnancy Category C
- Unknown safety in Lactation
X. Efficacy
- Lowers HBA1C by 0.5 to 1%
- Of the Meglitinides, Nateglinide is significantly weaker than Repaglinide (Prandin)
- Advantages in comparison to Sulfonylureas
- Low risk of Hypoglycemia (2.4%) than Sulfonylureas
- Effect depends on Ambient Blood Glucose levels
- No significant gastrointestinal side effects
- Minimal weight gain
- No lab monitoring required
- No significant Drug Interactions
- No Lactic Acidosis
- No adjustments needed (other than per meal)
- No adjustment in Congestive Heart Failure
- No adjustment for age
- No adjustment in Renal Insufficiency
- Disadvantages in comparison to Sulfonylureas
- Two to three times as expensive as Sulfonylureas
XI. Resources
Images: Related links to external sites (from Bing)
Related Studies
nateglinide (on 12/21/2022 at Medicaid.Gov Survey of pharmacy drug pricing) | ||
NATEGLINIDE 120 MG TABLET | Generic | $0.30 each |
NATEGLINIDE 60 MG TABLET | Generic | $0.27 each |
Ontology: nateglinide (C0903898)
Definition (NCI) | A phenylalanine derivative of the meglitinide class of agents with hypoglycemic activity. Nateglinide, compared to repaglitinide, binds with a higher affinity to the SUR1 subunit and with a faster onset of action and a shorter duration of action. This agent is metabolized by the cytochrome P450 isoenzyme CYP2C9, and, to a lesser extent, by CYP3A4. The parent drug and metabolites are mainly excreted in the urine and its half-life is about 1.5 hours. |
Concepts | Pharmacologic Substance (T121) , Amino Acid, Peptide, or Protein (T116) |
MSH | C060142 |
SnomedCT | 129496008, 134604002, 387070004 |
LNC | LP64443-2, MTHU026435 |
English | IPCCPA, N-((4-isopropylcyclohexyl)carbonyl)phenylalanine, nate-glinide, nateglinide (medication), NATEGLINIDE, nateglinide [Chemical/Ingredient], nateglinide, D-phenylalanine, N-((trans-4-(1-methylethyl)cyclohexyl)carbonyl)-, senaglinide, Nateglinide (product), Nateglinide (substance), Nateglinide |
Spanish | nateglinida (concepto no activo), nateglinida (producto), nateglinida (sustancia), nateglinida |
Ontology: Starlix (C1323198)
Concepts | Pharmacologic Substance (T121) , Organic Chemical (T109) |
MSH | C060142 |
English | starlix, Starlix, Novartis brand of nateglinide |